In the latest session, Pieris Pharmaceuticals Inc (NASDAQ: PIRS) closed at $0.18 down -9.15% from its previous closing price of $0.20. In other words, the price has decreased by -$0.0183 from its previous closing price. On the day, 2958118 shares were traded.
Ratios:
For a deeper understanding of Pieris Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.05 and its Current Ratio is at 2.05. In the meantime, Its Debt-to-Equity ratio is 0.40 whereas as Long-Term Debt/Eq ratio is at 0.00.
On May 14, 2019, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5.Robert W. Baird initiated its Outperform rating on May 14, 2019, with a $5 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 25 ’23 when KIRITSY CHRISTOPHER P bought 10,000 shares for $0.85 per share. The transaction valued at 8,500 led to the insider holds 20,000 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PIRS now has a Market Capitalization of 19.47M and an Enterprise Value of -13.04M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.38 while its Price-to-Book (P/B) ratio in mrq is 0.59. Its current Enterprise Value per Revenue stands at -0.28 whereas that against EBITDA is 1.06.
Stock Price History:
Over the past 52 weeks, PIRS has reached a high of $1.52, while it has fallen to a 52-week low of $0.14. The 50-Day Moving Average of the stock is 0.1727, while the 200-Day Moving Average is calculated to be 0.2549.
Shares Statistics:
For the past three months, PIRS has traded an average of 583.35K shares per day and 1.6M over the past ten days. A total of 98.85M shares are outstanding, with a floating share count of 91.49M. Insiders hold about 7.45% of the company’s shares, while institutions hold 38.97% stake in the company. Shares short for PIRS as of Feb 29, 2024 were 70.72k with a Short Ratio of 0.12, compared to 214.47k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.07% and a Short% of Float of 0.07%.
Earnings Estimates
There are 0 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.11. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.
Revenue Estimates
A total of 1 analysts believe the company’s revenue will be $2.24M this quarter.It ranges from a high estimate of $2.24M to a low estimate of $2.24M. As of the current estimate, Pieris Pharmaceuticals Inc’s year-ago sales were $5.85M, an estimated decrease of -61.70% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $2.24M, a decrease of -65.50% less than the figure of -$61.70% in the same quarter last year. There is a high estimate of $2.24M for the next quarter, whereas the lowest estimate is $2.24M.
A total of 1 analysts have provided revenue estimates for PIRS’s current fiscal year. The highest revenue estimate was $31.98M, while the lowest revenue estimate was $31.98M, resulting in an average revenue estimate of $31.98M. In the same quarter a year ago, actual revenue was $25.9M, up 23.50% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $6.62M in the next fiscal year. The high estimate is $6.62M and the low estimate is $6.62M. The average revenue growth estimate for next year is down -79.30% from the average revenue estimate for this year.
